Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients.

IF 0.7 Q4 ONCOLOGY
Case Reports in Oncology Pub Date : 2025-05-26 eCollection Date: 2025-01-01 DOI:10.1159/000546362
William Makis, Ilyes Baghli, Pierrick Martinez
{"title":"Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients.","authors":"William Makis, Ilyes Baghli, Pierrick Martinez","doi":"10.1159/000546362","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited.</p><p><strong>Case presentations: </strong>This report highlights 3 cases of patients with advanced cancer - including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after incorporating FBZ into their treatment regimens alongside other therapies (excluding chemotherapy). All three patients tolerated FBZ without any reported adverse effects, and remission was sustained during follow-up periods ranging from 11 months to nearly 3 years.</p><p><strong>Conclusion: </strong>FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology. Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"856-863"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215191/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000546362","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited.

Case presentations: This report highlights 3 cases of patients with advanced cancer - including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after incorporating FBZ into their treatment regimens alongside other therapies (excluding chemotherapy). All three patients tolerated FBZ without any reported adverse effects, and remission was sustained during follow-up periods ranging from 11 months to nearly 3 years.

Conclusion: FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology. Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use.

芬苯达唑作为抗癌剂?3例患者自我给药的病例系列分析。
背景:芬苯达唑(FBZ)是一种价格低廉且可广泛获得的抗寄生虫药物,用于兽医学,因其抗癌治疗的潜力而引起越来越多的关注。临床前研究表明,FBZ通过多种机制发挥其抗癌作用。虽然FBZ在体外和体内研究中都显示出希望,但目前支持其用于治疗转移性癌症的临床证据和疗效有限。病例介绍:本报告重点介绍了3例晚期癌症患者,包括乳腺癌、前列腺癌和黑色素瘤。两名患者在将FBZ与其他疗法(不包括化疗)合并后获得完全缓解,一名患者获得接近完全缓解。所有3例患者均耐受FBZ,无任何不良反应,并且在随访期间持续缓解,从11个月到近3年不等。结论:FBZ作为一种新的有前景的肿瘤治疗选择具有潜力。其促进肿瘤消退和疾病缓解的能力值得进一步的临床研究,以确定其疗效并优化其使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
151
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信